The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors.
Hesham M. Amin
Research Funding - EMD Serono
Gerald Steven Falchook
Consultant or Advisory Role - EMD Serono; EMD Serono
Honoraria - EMD Serono
Research Funding - EMD Serono; EMD Serono
Other Remuneration - EMD Serono
Siqing Fu
No relevant relationships to disclose
David S. Hong
No relevant relationships to disclose
Apostolia Maria Tsimberidou
No relevant relationships to disclose
Aung Naing
Research Funding - NIH
Jennifer J. Wheler
No relevant relationships to disclose
Sarina Anne Piha-Paul
No relevant relationships to disclose
Filip Janku
No relevant relationships to disclose
Manfred B Klevesath
Employment or Leadership Position - Merck KGaA
Virginie Jego
Employment or Leadership Position - Merck Serono
Andreas Johne
Employment or Leadership Position - Merck KGaA
Razelle Kurzrock
Research Funding - EMD Serono; Merck KGaA (B)